PDCD1 (PD-1) Promoter Methylation Predicts Outcome in Head and Neck Squamous Cell Carcinoma Patients

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 May 11

PMID 28487502

Citations 27

Authors

Diane Goltz

Heidrun Gevensleben

Joern Dietrich

Friederike Schroeck

Luka de Vos

Freya Droege

Glen Kristiansen

Andreas Schroeck

Jennifer Landsberg

Friedrich Bootz

Dimo Dietrich

Affiliations

Soon will be listed here.

Abstract

Background: Biomarkers that facilitate the prediction of disease recurrence in head and neck squamous cell carcinoma (HNSCC) may enable physicians to personalize treatment. In the current study, DNA promoter methylation of programmed cell death 1 (PDCD1, PD-1) was evaluated as a prognostic biomarker in HNSCC patients.

Results: High PDCD1 methylation (mPDCD1) was associated with a significantly shorter overall survival after surgical resection in both the discovery (HR = 2.24 [95%CI: 1.08-4.64], p = 0.029) and the validation cohort (HR = 1.54 [95%CI: 1.08-2.21], p = 0.017). In multivariate Cox proportional hazards analysis, PDCD1 methylation remained a significant prognostic factor for HNSCC (HR = 2.14 [95%CI: 1.19-3.84], p = 0.011). Further, mPDCD1 was strongly associated with the human papilloma virus (HPV) status.

Materials And Methods: mPDCD1 was assessed retrospectively in a discovery cohort of 120 HNSCC patients treated at the University Hospital of Bonn and a validation cohort of 527 HNSCC cases analyzed by The Cancer Genome Atlas Research Network.

Conclusions: PDCD1 methylation might aid the identification of HNSCC patients potentially benefitting from a radical or alternative treatment, particularly in the context of immunotherapies targeting PD-1/PD-L1.

Citing Articles

Distant metastasis of oral squamous cell carcinoma: immune escape mechanism and new perspectives on treatment.

He L, Wan M, Yang X, Meng H Discov Oncol. 2025; 16(1):257.

PMID: 40024975 PMC: 11872995. DOI: 10.1007/s12672-025-01997-3.

Recurrent and Metastatic Head and Neck Cancer: Mechanisms of Treatment Failure, Treatment Paradigms, and New Horizons.

Barham W, Stagg M, Mualla R, DiLeo M, Kansara S Cancers (Basel). 2025; 17(1.

PMID: 39796771 PMC: 11720666. DOI: 10.3390/cancers17010144.

Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer.

Eberly H, Sciscent B, Lorenz F, Rettig E, Goyal N Biomedicines. 2024; 12(2).

PMID: 38398017 PMC: 10886579. DOI: 10.3390/biomedicines12020415.

Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer.

Looi C, Foong L, Chung F, Khoo A, Loo E, Leong C Cell Biol Toxicol. 2023; 39(6):2501-2526.

PMID: 37755585 DOI: 10.1007/s10565-023-09830-9.

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy.

Ibrahim R, Saleh K, Chahine C, Khoury R, Khalife N, Cesne A Biomedicines. 2023; 11(7).

PMID: 37509517 PMC: 10377063. DOI: 10.3390/biomedicines11071878.

References

Kostareli E, Hielscher T, Zucknick M, Baboci L, Wichmann G, Holzinger D . Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients. Epigenetics. 2016; 11(1):61-73. PMC: 4846111. DOI: 10.1080/15592294.2015.1137414. View

Leemans C, Braakhuis B, Brakenhoff R . The molecular biology of head and neck cancer. Nat Rev Cancer. 2010; 11(1):9-22. DOI: 10.1038/nrc2982. View

Gevensleben H, Holmes E, Goltz D, Dietrich J, Sailer V, Ellinger J . PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget. 2016; 7(48):79943-79955. PMC: 5346762. DOI: 10.18632/oncotarget.13161. View

Cohen E, LaMonte S, Erb N, Beckman K, Sadeghi N, Hutcheson K . American Cancer Society Head and Neck Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016; 66(3):203-39. DOI: 10.3322/caac.21343. View

Bestor T, Edwards J, Boulard M . Notes on the role of dynamic DNA methylation in mammalian development. Proc Natl Acad Sci U S A. 2014; 112(22):6796-9. PMC: 4460495. DOI: 10.1073/pnas.1415301111. View

Chow L, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M . Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016; 34(32):3838-3845. PMC: 6804896. DOI: 10.1200/JCO.2016.68.1478. View

Lev Maor G, Yearim A, Ast G . The alternative role of DNA methylation in splicing regulation. Trends Genet. 2015; 31(5):274-80. DOI: 10.1016/j.tig.2015.03.002. View

Francisco L, Sage P, Sharpe A . The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236:219-42. PMC: 2919275. DOI: 10.1111/j.1600-065X.2010.00923.x. View

Schoppy D, Sunwoo J . Immunotherapy for Head and Neck Squamous Cell Carcinoma. Hematol Oncol Clin North Am. 2015; 29(6):1033-43. DOI: 10.1016/j.hoc.2015.07.009. View

10.

Holmes E, Jung M, Meller S, Leisse A, Sailer V, Zech J . Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine. PLoS One. 2014; 9(4):e93933. PMC: 3974851. DOI: 10.1371/journal.pone.0093933. View

11.

Youngblood B, Oestreich K, Ha S, Duraiswamy J, Akondy R, West E . Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity. 2011; 35(3):400-12. PMC: 3183460. DOI: 10.1016/j.immuni.2011.06.015. View

12.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

13.

Dietrich D, Hasinger O, Banez L, Sun L, van Leenders G, Wheeler T . Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn. 2012; 15(2):270-9. PMC: 5707187. DOI: 10.1016/j.jmoldx.2012.11.002. View

14.

Goltz D, Gevensleben H, Dietrich J, Ellinger J, Landsberg J, Kristiansen G . Promoter methylation of the immune checkpoint receptor () is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncoimmunology. 2016; 5(10):e1221555. PMC: 5087295. DOI: 10.1080/2162402X.2016.1221555. View

15.

Gillison M, Koch W, Capone R, Spafford M, Westra W, Wu L . Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92(9):709-20. DOI: 10.1093/jnci/92.9.709. View

16.

Goltz D, Gevensleben H, Grunen S, Dietrich J, Kristiansen G, Landsberg J . PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia. Leukemia. 2016; 31(3):738-743. DOI: 10.1038/leu.2016.328. View

17.

Ang K, Harris J, Wheeler R, Weber R, Rosenthal D, Nguyen-Tan P . Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1):24-35. PMC: 2943767. DOI: 10.1056/NEJMoa0912217. View

18.

Zur Hausen H . Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2(5):342-50. DOI: 10.1038/nrc798. View

19.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

20.

Li B, Severson E, Pignon J, Zhao H, Li T, Novak J . Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016; 17(1):174. PMC: 4993001. DOI: 10.1186/s13059-016-1028-7. View